Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug Abuse–Related Emergency Department Visits and Drug-Related Deaths — United States, 2010

Alcohol Involvement in Opioid Pain Reliever and Benzodiazepine Drug Abuse–Related Emergency Department Visits and Drug-Related Deaths — United States, 2010.

The analyses showed alcohol was involved in 18.5% of OPR and 27.2% of benzodiazepine drug abuse-related ED visits and 22.1% of OPR and 21.4% of benzodiazepine drug-related deaths. These findings indicate that alcohol plays a significant role in OPR and benzodiazepine abuse. Interventions to reduce the abuse of alcohol and these drugs alone and in combination are needed.

JAMA – Treating Prescription Opioid Dependence

JAMA Network | JAMA | Treating Prescription Opioid Dependence.

Conclusions and Relevance This study represents a rigorous experimental evaluation of outpatient buprenorphine stabilization, brief taper, and naltrexone maintenance for treatment of PO dependence. Results suggest that a meaningful subset of PO-dependent outpatients may respond positively to a 4-week

 

Naltrexone maintenance?  I bet they’ll lost weight too.

http://underwritingsolutionsllc.com/2014/09/14/fda-approves-bupropionnaltrexone-contrave-for-obesity/

Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC – WebMD

Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC – WebMD.

Deaths from overdoses of drugs such as hydrocodone (Vicodin), morphine and oxycodone (Oxycontin) climbed from 1.4 per 100,000 people to 5.4 per 100,000, according to the U.S. Centers for Disease Control and Prevention.

That means about 3,000 people died in 1999 from unintentional overdoses. By 2011, that number was up to nearly 12,000 deaths, the report said.

FDA Okays Naloxegol Movantik in Opioid-Induced Constipation

If you read the source article you’ll never look at constipation the same way ever again. Better dig deeper to find out why your applicant is constipated.  It may not be just a horrible diet and lack of dietary fiber.

And yet another FDA approved drug to counteract adverse effects from another FDA approved drug.

FDA Okays Naloxegol Movantik in Opioid-Induced Constipation.

The US Food and Drug Administration (FDA) has approved naloxegol (Movantik, AstraZeneca Pharmaceuticals), a peripherally acting opioid receptor antagonist, for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain.

OIC is a common adverse effect of opioid use. An estimated 40% to 80% of patients receiving long-term opioid therapy experience OIC, which can be severe enough to cause discontinuation of opioid therapy.